Zydus Lifesciences Ltd.

Zydus Cadila has received the final approval from the USFDA to market Lansoprazole DR Capsules in different strengths of 15mg and 30mg. The drug falls in the anti-ulcerant segment. The estimated sales in 2012 as per IMS for Lansoprazole DR Capsules were $501 million.

The group has now 81 approvals and has so far filed 186 ANDAs since the commencement of filing process in FY2003-04.

Cadila Healthcare, the flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.